Clinical Trial Detail

NCT ID NCT03029403
Title Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

peritoneal carcinoma

ovarian carcinoma

fallopian tube carcinoma

Therapies

Cyclophosphamide + DPX-Survivac + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.